Board of Scientific Counselors, National Center for Health Statistics (BSC, NCHS), 4303 [2016-01442]
Download as PDF
<![CDATA[
Federal Register / Vol. 81, No. 16 / Tuesday, January 26, 2016 / Notices
for selection of potential nominees to
replace members whose terms will end
on June 30, 2017. Selection of members
is based on candidates’ qualifications to
contribute to the accomplishment of
ACIP objectives (https://www.cdc.gov/
vaccines/acip/). The U.S.
Department of Health and Human
Services policy stipulates that
committee membership be balanced in
terms of professional training and
background, points of view represented,
and the committee’s function.
Consideration is given to a broad
representation of geographic areas
within the U.S., with equitable
representation of the sexes, ethnic and
racial minorities, and persons with
disabilities. Nominees must be U.S.
citizens, and cannot be full-time
employees of the U.S. Government.
Candidates should submit the following
items:
D Current curriculum vitae, including
complete contact information
(telephone numbers, mailing address,
email address)
D At least one letter of
recommendation from person(s) not
employed by HHS *
The deadline for receipt of all
application materials (for consideration
for term beginning July 1, 2017) is
November 4, 2016. All files must be
submitted electronically as email
attachments to: Ms. Stephanie Thomas,
ACIP Secretariat, Email: SThomas5@
cdc.gov.
Nominations may be submitted by the
candidate him- or herself, or by the
person/organization recommending the
candidate.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
* Candidates may submit letter(s) from
current HHS employees if they wish, but at
least one letter must be submitted by a
person not employed by HHS (e.g., CDC,
NIH, FDA, etc.).
[Docket No. FDA–2015–D–4852]
mstockstill on DSK4VPTVN1PROD with NOTICES
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2016–01443 Filed 1–25–16; 8:45 am]
BILLING CODE 4163–18–P
VerDate Sep<11>2014
21:57 Jan 25, 2016
Jkt 238001
Centers for Disease Control and
Prevention
Board of Scientific Counselors,
National Center for Health Statistics
(BSC, NCHS)
Notice of Cancellation: This notice
was published in the Federal Register
on December 23, 2015, Volume 80,
Number 246, pages 79899–79900. The
meeting previously scheduled to
convene on January 21–22, 2016, has
been cancelled.
Contact Person for More Information:
Virginia S. Cain, Ph.D., Director of
Extramural Research, NCHS/CDC, 3311
Toledo Road, Room 7208, Hyattsville,
Maryland 20782, Telephone (301) 458–
4395, Fax (301) 458–4020, Email:
vcain@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2016–01442 Filed 1–25–16; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Design Considerations and Premarket
Submission Recommendations for
Interoperable Medical Devices; Draft
Guidance for Industry and Food and
Drug Administration Staff; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA or Agency) is
announcing the availability of the draft
guidance entitled ‘‘Design
Considerations and Pre-market
Submission Recommendations for
Interoperable Medical Devices’’. FDA is
issuing this draft guidance to assist
industry and FDA staff in identifying
specific considerations related to the
ability of electronic medical devices to
safely and effectively exchange and use
SUMMARY:
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
4303
exchanged information. This document
highlights considerations that should be
included in the development and design
of interoperable medical devices and
provides recommendations for the
content of premarket submissions and
labeling for such devices. This draft
guidance is not final nor is it in effect
at this time.
DATES: Although you can comment on
any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the Agency
considers your comment of this draft
guidance before it begins work on the
final version of the guidance, submit
either electronic or written comments
on the draft guidance by March 28,
2016.
ADDRESSES: You may submit comments
as follows:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Division of Dockets
Management, FDA will post your
comment, as well as any attachments,
except for information submitted,
marked and identified, as confidential,
if submitted as detailed in
‘‘Instructions’’.
E:\FR\FM\26JAN1.SGM
26JAN1
]]>Agencies
[Federal Register Volume 81, Number 16 (Tuesday, January 26, 2016)]
[Notices]
[Page 4303]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-01442]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Board of Scientific Counselors, National Center for Health
Statistics (BSC, NCHS)
Notice of Cancellation: This notice was published in the Federal
Register on December 23, 2015, Volume 80, Number 246, pages 79899-
79900. The meeting previously scheduled to convene on January 21-22,
2016, has been cancelled.
Contact Person for More Information: Virginia S. Cain, Ph.D.,
Director of Extramural Research, NCHS/CDC, 3311 Toledo Road, Room 7208,
Hyattsville, Maryland 20782, Telephone (301) 458-4395, Fax (301) 458-
4020, Email: vcain@cdc.gov.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities for
both the Centers for Disease Control and Prevention and the Agency for
Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2016-01442 Filed 1-25-16; 8:45 am]
BILLING CODE 4163-18-P
